Relationship of health‐related quality of life to treatment adherence and sustained response in chronic hepatitis C patients
David Bernstein, Leah Kleinman, Chris M. Barker, Dennis A. Revicki, Jesse Green – 30 December 2003 – Interferon therapy may exacerbate health‐related quality of life (HRQL) deficits associated with hepatitis C virus (HCV) early in the course of therapy. Treatment with polyethylene glycol–modified interferon (peginterferon) alfa‐2a (40 kd) provides improved sustained response over interferon alfa‐2a, but its effect on HRQL is unknown.